DailyPay Improves Employee Retention, Productivity, and Morale According to New Study

/

New research from Arizent/Employee Benefits News demonstrates the positive impact DailyPay can have for employers, many of whom are still challenged with a tight labor market. According to the study commissioned by DailyPay, the leader in earned wage access, employees stay longer, are more productive, and are more motivated at work when they have the highly sought-after financial wellness benefit. Those employees also pick up extra shifts, are less likely to look for a new job, and exude higher morale.

The study also reveals that DailyPay is among the top three benefits employees engage with in over half the instances, signifying its importance among companies’ total rewards/benefits packages.

The noteworthy findings revealed in the study include:

Click here for more…..

MOBI - LAUNCH PITCH AT THE PHOCUSWRIGHT CONFERENCE 2023

/

Founded 13 years ago, Mobi is a B2B technology company with an agent-facing, collaborative artificial intelligence platform. The company’s solutions work horizontally through the industry, addressing the needs of agents in travel agencies, airlines, hotels, cruise and travel management companies.

The company’s “agent for agents” technology is designed to help agents reduce the time taken to put a trip together, leaving time for the agent to focus on building a relationship with the customer.

Click here for more…..

Prolacta Starts Drug Development

/

Since its founding in 1999, Duarte-based Prolacta Bioscience Inc. has been chiefly focused on supplying human breast milk-based nutritional products for premature and critically ill infants to hospitals and other health care providers.

The business has had its share of ups and downs over the years, including weathering a contamination scare that rocked the industry a decade ago. But now, Prolacta has unveiled a new business line: drug development. The company has spent the past several years researching and developing what it claims is the first drug made from human milk. The drug aims to boost immunity in patients who have undergone stem cell transplants to combat blood cancers.

Last month, Prolacta announced that researchers at nearby City of Hope – also based in Duarte – had dosed the first patient with the drug to initiate a Phase 2a clinical trial. It’s a major step in what will likely be a years-long process costing well over $100 million to bring the drug to the U.S. Food and Drug Administration for approval and eventually to market.

Click here for more…..